Earnings : What to expect NASDAQ:ZNTL, NASDAQ:LUNA, NASDAQ:LMNL, NASDAQ:BHTG

ZENTALIS PHARMACEUTICALS (NASDAQ:ZNTL) EARNINGS INFORMATION (NASDAQ:ZNTL)

Zentalis Pharmaceuticals last released its earnings data on May 17th, 2021. The reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.97) by $0.27. Zentalis Pharmaceuticals has generated $0.00 earnings per share over the last year. Zentalis Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 12th, 2021 based off prior year’s report dates.

IS ZENTALIS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:ZNTL)

6 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals

LUNA INNOVATIONS (NASDAQ:LUNA) EARNINGS INFORMATION (NASDAQ:LUNA)

Luna Innovations last posted its quarterly earnings data on May 16th, 2021. The scientific and technical instruments company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by $0.02. Luna Innovations has generated $0.17 earnings per share over the last year and currently has a price-to-earnings ratio of 57.3. Luna Innovations has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 5th, 2021 based off prior year’s report dates.

IS LUNA INNOVATIONS A BUY RIGHT NOW? (NASDAQ:LUNA)

1 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Luna Innovations in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Luna Innovations stock.
Luna Innovations

LIMINAL BIOSCIENCES (NASDAQ:LMNL) EARNINGS INFORMATION (NASDAQ:LMNL)

Liminal BioSciences last issued its quarterly earnings results on May 16th, 2021. The reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.05. Liminal BioSciences has generated ($10.94) earnings per share over the last year. Liminal BioSciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 9th, 2021 based off prior year’s report dates.

IS LIMINAL BIOSCIENCES A BUY RIGHT NOW? (NASDAQ:LMNL)

5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Liminal BioSciences in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Liminal BioSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNL, but not buy additional shares or sell existing shares.
Liminal BioSciences

BIOHITECH GLOBAL (NASDAQ:BHTG) EARNINGS INFORMATION (NASDAQ:BHTG)

BioHiTech Global last announced its quarterly earnings results on May 17th, 2021. The reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. BioHiTech Global has generated $0.00 earnings per share over the last year. BioHiTech Global has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS BIOHITECH GLOBAL A BUY RIGHT NOW? (NASDAQ:BHTG)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for BioHiTech Global in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” BioHiTech Global stock.
BioHiTech Global